Dashboard Tools Market News Investing Ideas Pricing About Us
Sign Up
Log in
Celyad Oncology SA banner

Celyad Oncology SA
F:1C0

Watchlist Manager
Celyad Oncology SA Logo
Celyad Oncology SA
F:1C0
Watchlist
Price: 0.142 EUR 9.23%
Market Cap: €1.7m
Write Note Create Alert Ask AI

Intrinsic Value

1C0 doesn't have a meaningful market cap.

The intrinsic value of one 1C0 stock under the Base Case scenario is hidden EUR. Compared to the current market price of 0.142 EUR, Celyad Oncology SA is hidden .

Valuation Methods:
DCF Value
N/A
Relative Value
Hidden
DCF Value
N/A
Relative Value
Hidden
1C0 Intrinsic Value
HIDDEN
Show

Valuation History
Celyad Oncology SA

Intrinsic Value History
Dive into the past to invest in the future

1C0 looks overvalued. Yet it might still be cheap by its own standards. Some stocks live permanently above intrinsic value; Historical Valuation reveals whether 1C0 usually does or if today's premium is unusual.

Learn how current stock valuations stack up against historical averages to gauge true investment potential.

Show Historical Valuation
What is Valuation History?
Ask AI Assistant
What other research platforms think about 1C0?

Let our AI compare Alpha Spread’s intrinsic value with external valuations from Simply Wall St, GuruFocus, ValueInvesting.io, Seeking Alpha, and others.

Discover External Valuations
Why is 1C0 valued this way?

Let our AI break down the key assumptions behind the intrinsic value calculation for Celyad Oncology SA.

Explain Valuation
Compare 1C0 to

Fundamental Analysis

Financials
Efficiency

Earnings Waterfall
Celyad Oncology SA

Wall St
Price Targets

Dividends

Celyad Oncology SA
does not pay dividends
Shareholder Yield
Buyback Yield
HIDDEN
Debt Paydown Yield
HIDDEN

Competitive Landscape

See Also

Summary
1C0 intrinsic value, competitors valuation, and company profile.
DCF Valuation
1C0 stock valuation using Discount Cash Flow valuation method.
Relative Valuation
1C0 stock valuation using valuation multiples.
Wall Street Estimates
1C0 price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
1C0 stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
What is the Intrinsic Value of one 1C0 stock?

The intrinsic value of one 1C0 stock under the Base Case scenario is hidden EUR.

Is 1C0 stock undervalued or overvalued?

Compared to the current market price of 0.142 EUR, Celyad Oncology SA is hidden .

Back to Top
ALPHA SPREAD
Follow us
Join more than 316,200+ value investors using Alpha Spread
Create Free Account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2026 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.